Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020

Interim results from Canada's Sentinel Practitioner Surveillance Network show that during a season characterised by early co-circulation of influenza A and B viruses, the 2019/20 influenza vaccine has provided substantial protection against medically-attended influenza illness. Adjusted VE overall was 58% (95% confidence interval (CI): 47 to 66): 44% (95% CI: 26 to 58) for A(H1N1)pdm09, 62% (95% CI: 37 to 77) for A(H3N2) and 69% (95% CI: 57 to 77) for influenza B viruses, predominantly B/Victoria lineage.

[1]  Job vacancy at the European Centre for Disease Prevention and Control (ECDC) , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[2]  M. Valenciano,et al.  Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[3]  A. Monto,et al.  Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011–2012 to 2016–2017 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  S. Hensley,et al.  Antigenic assessment of the H3N2 component of the 2019-2020 Northern Hemisphere influenza vaccine , 2020, Nature Communications.

[5]  M. Valenciano,et al.  Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15–64-year-olds in Europe: exploration by birth cohort , 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[6]  M. Zambon,et al.  Influenza imprinting in childhood and the influence on vaccine response later in life , 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[7]  D. Skowronski,et al.  Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV) , 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[8]  L. Grohskopf,et al.  Update: Influenza Activity — United States and Worldwide, May 19–September 28, 2019, and Composition of the 2020 Southern Hemisphere Influenza Vaccine , 2019, MMWR. Morbidity and mortality weekly report.

[9]  Ha T. Nguyen,et al.  Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011–2018 , 2019, Scientific Reports.

[10]  D. Skowronski,et al.  Vaccine Effectiveness Against Lineage-matched and -mismatched Influenza B Viruses Across 8 Seasons in Canada, 2010–2011 to 2017–2018 , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Nicole M. Bouvier,et al.  Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance , 2018, The Journal of clinical investigation.

[12]  D. Skowronski,et al.  Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015–2016 Season in Canada , 2017, The Journal of infectious diseases.

[13]  D. Skowronski,et al.  Age-Related Differences in Influenza B Infection by Lineage in a Community-Based Sentinel System, 2010–2011 to 2015–2016, Canada , 2017, The Journal of infectious diseases.

[14]  Peng Wu,et al.  Population-Based Pediatric Hospitalization Burden of Lineage-Specific Influenza B in Hong Kong, 2004–2014 , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  D. Skowronski,et al.  Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019 , 2016, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[16]  D. Skowronski,et al.  Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013-2014 Influenza Season. , 2015, The Journal of infectious diseases.

[17]  K. Ikuta,et al.  Emerging Antigenic Variants at the Antigenic Site Sb in Pandemic A(H1N1)2009 Influenza Virus in Japan Detected by a Human Monoclonal Antibody , 2013, PloS one.

[18]  James E. Crowe,et al.  Influenza Human Monoclonal Antibody 1F1 Interacts with Three Major Antigenic Sites and Residues Mediating Human Receptor Specificity in H1N1 Viruses , 2012, PLoS pathogens.

[19]  D. Skowronski,et al.  Cross-Lineage Influenza B and Heterologous Influenza A Antibody Responses in Vaccinated Mice: Immunologic Interactions and B/Yamagata Dominance , 2012, PloS one.

[20]  N. Bovin,et al.  Escape mutants of pandemic influenza A/H1N1 2009 virus: variations in antigenic specificity and receptor affinity of the hemagglutinin. , 2012, Virus research.

[21]  D. Skowronski,et al.  Influenza B/Victoria Antigen Induces Strong Recall of B/Yamagata But Lower B/Victoria Response in Children Primed With Two Doses of B/Yamagata , 2011, The Pediatric infectious disease journal.

[22]  Xiyan Xu,et al.  Serologic assays for influenza surveillance, diagnosis and vaccine evaluation , 2011, Expert review of anti-infective therapy.